This department is the backbone and also the life force of the omicron pharma The drug subjected to drug development undergoes number of trials and are screened at different stages to produce a final potent drug intended for the treatment of various diseases. During this process various properties are checked to see whether the drug is non-toxic to living system and is therapeutic or not. Using suitable excipients and technological preparations the active substances are formulated into final dosage form. The last product is the Actual composition of preparation, manufacturing specification. Drug formulation can have a substantial impact on almost every quality characteristic of an API including potency, bioavailability, solubility, dosage, route of administration and stability. In immune offers parenteral drug formulation R&D services for primary stage and preclinical candidates with a special prominence in nanoparticle based drug delivery technology.